Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORIC: Cediranib and Gefitinib in Recurrent Glioblastoma
NCT01310855Phase 2Terminated
- Sponsor
- University College London
- Start
- May 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in glioblastoma (GBM), sponsored by University College London. Started May 2011; status: terminated.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01310855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01310855.